Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
Ella Day | June 10, 2025 | News story | Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing | Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims to highlight the company’s ongoing research efforts and pipeline developments targeting this rare neurological condition.
The event will feature expert insights into the GBS treatment landscape. David Cornblath, professor emeritus of neurology at Johns Hopkins University and former director of its EMG Laboratory, and Simon Rinaldi, head of the inflammatory neuropathy research programme at the University of Oxford, will provide presentations covering the unmet clinical need, current treatment landscape, the role of Immunoglobulin G (IgG) in GBS, and recent advances in scientific understanding. Rinaldi’s research group is closely linked to the International GBS Outcome Study (IGOS) database and has contributed to major clinical trials into the condition.
Hansa’s leadership team will also present updates on its autoimmune research strategy, including key milestones for its IgG-cleaving enzyme technology platform. Speakers will include Hitto Kaufmann, chief R&D officer, and Elisabeth Sonesson, vice president and global franchise lead for autoimmunity.
Hansa is developing targeted treatments for rare immunological conditions, using its platform to modulate immune responses in diseases where IgG plays a key role.
GBS is a rare inflammatory disorder of the peripheral nervous system. Symptoms can include nerve pain, muscle weakness, breathing difficulties and, in severe cases, paralysis.
Ella Day
10/6/25
Related Content
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating …
